Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
[Neurodegeneration in multiple sclerosis and the neuroprotective effect of glatiramer acetate: a literature review].
Cerebrovascular hemodynamic changes in multiple sclerosis patients during head-up tilt table test: effect of high-dose intravenous steroid treatment.
[Clinically isolated syndrome.]
Lack of association between AQP4 polymorphisms and risk of inflammatory demyelinating disease in a Korean population.
Neuromyelitis optica in child: diagnostic and therapeutic challenges.
Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis.
Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.
Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica.
A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis.
Repeated sugammadex usage in a patient with multiple sclerosis: a case report.
Neurodegenerative diseases and therapeutic strategies using iron chelators.
Revisiting the management of fatigue in multiple sclerosis in the context of rehabilitation: a narrative review of current evidence.
A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis.
Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors b20-4.1.1 and angiostatin (k1-3).
TET2 gene expression and 5-hydroxymethylcytosine level in multiple sclerosis peripheral blood cells.
Targeting calpain-mediated proteolysis and peptide signaling as a strategy to reduce injury in multiple sclerosis.
Isoprostanes and Neuroprostanes as Biomarkers of Oxidative Stress in Neurodegenerative Diseases.
Multiple sclerosis and family planning.
Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis.
Trigeminal neuralgia: New classification and diagnostic grading for practice and research.
Neuregulin-1 controls an endogenous repair mechanism after spinal cord injury.
Fatigue and its association with sleep disorders, depressive symptoms and anxiety in patients with multiple sclerosis.
Quantitative MRI Analysis of the Brain after Twenty-Two Years of Neuromyelitis Optica Indicates Focal Tissue Damage.
Pages
« first
‹ previous
…
346
347
348
349
350
351
352
353
354
…
next ›
last »